Gold prices hold near record highs ahead of Fed rate decision
Investing.com - B.Riley initiated coverage on Theravance Biopharma (NASDAQ:TBPH) with a Buy rating and a $28.00 price target, citing the company’s strong position following a strategic review process. The company has shown impressive momentum, with a 69% return over the past year and currently trades near its 52-week high of $14.55. According to InvestingPro data, the company maintains a "GREAT" financial health score of 3.33.
The research firm highlighted Theravance’s recent $275 million cash influx from monetizing its non-core asset, GSK’s Trelegy, which strengthens the company’s financial position as it focuses on two key growth drivers.
B.Riley identified Viatris-partnered Yupelri for chronic obstructive pulmonary disease (COPD) as a significant asset, noting it currently generates approximately $270 million in annualized revenue and is growing at about 20% year-over-year.
The firm also emphasized the potential of ampreloxetine, which is being evaluated in a fully enrolled Phase 3 CYPRESS trial for treating symptomatic neurogenic orthostatic hypotension in Multiple System Atrophy patients, describing the upcoming trial readout as "highly de-risked."
B.Riley believes Theravance’s enterprise value of approximately $400 million significantly undervalues ampreloxetine’s peak risk-adjusted sales potential of around $550 million, as well as the durable cash flow from Yupelri, which benefits from recent patent litigation settlements delaying generic competition for over a decade. For deeper insights into Theravance’s valuation and growth potential, including 12+ additional ProTips and comprehensive financial analysis, visit InvestingPro.
In other recent news, Theravance Biopharma reported strong financial results for the second quarter of 2025, with earnings per share (EPS) of $1.08, surpassing analyst expectations of $0.67. The company’s revenue also exceeded estimates, reaching $26.2 million compared to the projected $15.92 million. This performance marked a significant surprise for investors. Additionally, Theravance Biopharma has completed the enrollment in the open-label portion of its Phase 3 CYPRESS trial for neurogenic orthostatic hypotension, with data expected in the first quarter of 2026. In legal developments, the company reached a settlement with Cipla Limited and others regarding patent litigation over YUPELRI inhalation solution. Furthermore, BTIG reiterated a Buy rating on Theravance’s stock with a $25.00 price target, citing positive trends in the CYPRESS trial. Leerink Partners also raised its price target on Theravance to $13.00 from $10.00, maintaining a Market Perform rating. This adjustment followed the completion of Theravance’s Trelegy royalty sale and a milestone payment from Yupelri China approval.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.